Bosutinib (BOS) versus Imatinib (IMA) for newly diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-year results from the BFORE trialT. H. Bruemmendorf,J. E. Cortes,P. Le Coutre, K. Jentsch-Ullrich,D. Milojkovic,C. Gambacorti-Passerini,V Garcia-Gutierrez,P. H. Rousselot,E. Leip,S. Purcell,A. Yver,A. Viqueira,M. W. Deininger,A. HochhausONCOLOGY RESEARCH AND TREATMENT（2021）引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
